Skip to main content

Table 2 Patient demographics

From: Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response

Sex (no.)

 Male

25 (59.5%)

 Female

17 (40.5%)

 Median age

59.5 yrs. (38–81)

Imaging pattern on WB-MRI (no.)

 Focal

25 (59.5%)

 Diffuse

5 (11.9%)

 Focal and diffuse

5 (11.9%)

 Salt and pepper

7 (16.7%)

Heavy chain (no.)

 IgA

4 (9.5%)

 IgD

3 (7.1%)

 IgG

19 (45.2%)

 Light chain only

16 (38.1%)

Light chain (no.)

 Kappa

22 (52.4%)

 Lambda

20 (47.6%)

International staging system (no.)

 Stage I

7 (16.7%)

 Stage II

20 (47.6%)

 Stage III

15 (35.7%)

Laboratory findings

 Bone marrow plasma cell (%)

39.7 ± 29.7

 Serum M-protein (g/dL)

2.1 ± 2.6

 Urine M-protein (mg/dL)

827.9 ± 2549.0

 Serum FLC ratio†

458.9 ± 736.0

 Absolute FLC difference (mg/L)

3880.7 ± 5612.6

 Beta-2 microglobulin (ug/mL)

7.3 ± 8.8

 Albumin (g/dL)

3.3 ± 0.7

 Calcium (mg/dL)

9.3 ± 1.6

 Creatinine (mg/dL)

1.7 ± 1.6

 Hemoglobin (g/dL)

10.3 ± 2.1